Specifically, 36% of subjects on a 450mg dose and 48% on a 900mg dose achieved the primary endpoint versus 20% for the placebo group. In the advanced therapy (AT)-experienced subgroup, 29% on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback